Omega Therapeutics Inc (OMGA) News

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a...

Form 8-K - Current report

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a...

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Omega Therapeutics Announces Updates to its Board of Directors

Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Continued Enrollment in Monotherapy Dose Escalation Stage of Phase 1/2 MYCHELANGELO™ I Study; Preliminary...

Form 8-K - Current report

Form 8-K - Current report